A new brief from Avalere Health argues that, if a multisource market for biologic drugs is to emerge in the United States, originator biologics and biosimilars must be able to gain market share commensurate to the value they offer to the healthcare system, and a variety of policy options are available to create the necessary conditions for true competition.
A new brief from Avalere Health argues that, if a multi-source market for biologic drugs is to emerge in the United States, originator biologics and biosimilars must be able to gain market share commensurate to the value they offer to the healthcare system, and a variety of policy options are available to create the necessary conditions for true competition.
In Europe, where the first biosimilar was approved in 2006, say the authors, “competitive biologics have generally gained increasing market share over time,” and biosimilars now make up one-fourth of all biologics sales for product with expired EU patents. While uptake varies by nation, some biosimilars, like filgrastim, have achieved a market penetration of 60% to 80%, and price discounts for some of the earlier and smaller biologic drugs have ranged from 15% to 40%.
European nations have used a variety of policies to drive the biosimilars market; Norway and Denmark use a tender system that has resulted in a 70% negotiated discount for infliximab biosimilars. Germany uses a prescribing quota and provider education programs, which have resulted in 50% volume uptake of biosimilars. In the United Kingdom, where the National Institute for Health and Care Excellence conducts health technology assessments for drugs used in its national system, biosimilars have driven price reductions of 25% for infliximab, 18% for epoetin, and 8% for filgrastim. UK patient access has increased by 104% for filgrastim since the advent of biosimilars.
By contrast, Ireland, which has thus far not implemented proactive policies to encourage biosimilar use, has seen little associated uptake. The nation is now undertaking an effort to create a more sustainable environment for biologics, and it is encouraging physician-directed switching.
Other highly regulated markets have employed their own incentives and have seen degrees of success; Australia uses a system in which the Pharmaceutical Benefits Advisory Committee may designate biosimilars as being subject to automatic pharmacy-level substitution on a product-by-product basis. Individual switching, notes Avalere, has been limited in Australia, as patients have fixed co-payment amounts that do not incentivize nonmedical switches.
In Canada, public listing of biosimilars has been slow after product approval, and although payers encourage new patients to begin treatment with a biosimilar, few established patients are switching their treatments.
The Republic of Korea implemented a “ceiling price” policy in 2012, under which originator and multi-source products are reimbursed at a single rate that drops when a competitor enters the market. This policy has led to a decline in spending, yet biosimilar uptake has been low, as the system provides no incentive to switch treatments.
In the United States, with its young biosimilars market, market forces determine the price of biologics and biosimilars. Avalere says that, according to its background research, payers expect to achieve a cost discount if they are to cover a biosimilar product, and they expect approximately 15% to 40% savings to help offset the administrative costs of switching patients, implementing educational programs, and creating utilization management strategies. If the price of a biosimilar is too near that of the originator, there is little incentive to undertake a costly endeavor to educate prescribers, and contracting with reference product sponsors may further complicate competition.
The report concludes that, while the United States has a number of models on which to base its own policy framework, it must actively pursue lower costs and increased patient access, as competition will not succeed without adjustments to policy.
“International experience suggests that, absent the specific incentives to help biosimilars achieve market share in exchange for competitive prices, a stable multisource specialty market in the [United States] and other markets may not flourish,” say the authors.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
April 3rd 2024Although tender systems are a common strategy to encourage biosimilar utilization across Europe, policies like automatic substitution are rarely utilized, according to a systematic review of European policies and biosimilar uptake.